All Posts

Mini StartUp Review & Example for Fractional BD Opportunity By Henning Mann, PhD | HM.BioConsulting 3–5 minute read Download the File “Longevity research is evolving. AI and automation are accelerating drug discovery. In this space Ora Biomedical is one to watch.” Background: Aging as a Modifiable Endpoint Aging is the single greatest risk factor for most chronic diseases, yet for decades, drug discovery pipelines have focused on treating symptoms rather than addressing upstr

Download the article: A conversation between Elizabeth (Lizzy) Crist, Business Development Manager & Technical Lead (USA), AIM Biotech and Henning Mann, PhD, Founder & CEO, HM.BioConsulting, former Sen. Dir. Applied Science, Nortis Inc.,   Executive Intro With the FDA, NIH, and GAO each advancing the shift toward human-based preclinical models , Organ-on-Chip (OoC) and broader Microphysiological Systems (MPS) technologies have been moved into the spotlight and given unprecede

Review Opinion: Henning Mann, PhD, HM.BioConsulting LLC Download PDF: The more conversations we have with clients and prospects, the more...

Henning Mann, PhD, HM.BioConsulting   🚨 The Policy Shift We've Been Waiting For In 2025, the FDA, in collaboration with the National...

Opinion, Henning Mann, PhD, HM.BioConsulting   In today’s tight funding climate and intense competitive pressure, emerging and...